Ifebemtinib tosylate
Based on 3 publication(s) in Google Scholar
Ifebemtinib (tosylate) (BI-853520 (tosylate); IN-10018 (tosylate)) is a highly selective PTK2 kinase inhibitor. Ifebemtinib (tosylate) demonstrates anti-tumor activity. Ifebemtinib (tosylate) inhibits FAK autophosphorylation in prostate carcinoma cells. Ifebemtinib (tosylate) can inhibit spheroid formation and orthotopic tumor growth in vivo. Ifebemtinib (tosylate) can be studied in anticancer research such as solid tumors, breast cancer, and malignant pleural mesothelioma.
For research use only. We do not sell to patients.
- CAS No.: 2761021-80-9
- Formula: C35H36F4N6O7S
- Molecular Weight:760.75
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ifebemtinib tosylate
More
Biological Activity
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2761021-80-9
-
Molecular Weight 760.75
-
Formula C35H36F4N6O7S
-
SMILES
O=C(C1=C(F)C=C(NC2=NC=C(C(F)(F)F)C(OC3=CC=CC4=C3C(N(C4)C)=O)=N2)C(OC)=C1)NC5CCN(CC5)C.O=S(O)(C6=CC=C(C)C=C6)=O
-
Synonyms
BI-853520 tosylate; IN-10018 tosylate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Sci Adv
Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis. [Abstract]2026 Jan 30;12(5):eady8382. PMID: 41616055 -
Anticancer Drugs
Upregulation of CDC25B by transcription factor TEAD4 drives invasion and inhibits cisplatin sensitivity through cell adhesion in stomach adenocarcinoma. [Abstract]2024 Nov 1;35(10):922-931. PMID: 39079173 -
bioRxiv
Decreased substrate stiffness leads to mitochondrial dysfunctions and Endothelial to Mesenchymal transition through Focal Adhesion Kinase activity in corneal endothelial cells. [Abstract]2025 Dec 2:2025.11.08.687366. PMID: 41279848
Purity & Documentation
References
[1]. Laszlo, V., et al., (2019). The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. Journal of molecular medicine (Berlin, Germany), 97(2), 231–242. [Content Brief]
[2]. Verheijen, R. B., et al., (2019). Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520. Targeted oncology, 14(1), 67–74. [Content Brief]
[3]. Tiede, S., et al., (2018). The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer. Oncogenesis, 7(9), 73. [Content Brief]
[4]. Marabelle, A., et al., (2020). Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. The Lancet. Oncology, 21(10), 1353–1365. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ifebemtinib tosylate Related Classifications
HY-122844B Related Classifications
Powered by Bioz